CN104302319B - 包含突变的糖蛋白c的重组马疱疹病毒-1疫苗及其用途 - Google Patents
包含突变的糖蛋白c的重组马疱疹病毒-1疫苗及其用途 Download PDFInfo
- Publication number
- CN104302319B CN104302319B CN201380023248.3A CN201380023248A CN104302319B CN 104302319 B CN104302319 B CN 104302319B CN 201380023248 A CN201380023248 A CN 201380023248A CN 104302319 B CN104302319 B CN 104302319B
- Authority
- CN
- China
- Prior art keywords
- ehv
- strain
- restructuring
- gene
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
- C12N2710/16762—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (18)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261613151P | 2012-03-20 | 2012-03-20 | |
US61/613,151 | 2012-03-20 | ||
PCT/US2013/032491 WO2013142371A1 (en) | 2012-03-20 | 2013-03-15 | Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104302319A CN104302319A (zh) | 2015-01-21 |
CN104302319B true CN104302319B (zh) | 2016-08-24 |
Family
ID=48193269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380023248.3A Active CN104302319B (zh) | 2012-03-20 | 2013-03-15 | 包含突变的糖蛋白c的重组马疱疹病毒-1疫苗及其用途 |
Country Status (16)
Country | Link |
---|---|
US (2) | US8916371B2 (zh) |
EP (1) | EP2827897B1 (zh) |
JP (1) | JP6201166B2 (zh) |
CN (1) | CN104302319B (zh) |
AR (2) | AR090450A1 (zh) |
AU (1) | AU2013235423B2 (zh) |
BR (1) | BR112014023414B1 (zh) |
CA (1) | CA2867893C (zh) |
ES (1) | ES2711878T3 (zh) |
HK (1) | HK1201205A1 (zh) |
HU (1) | HUE042396T2 (zh) |
MX (1) | MX355443B (zh) |
NZ (1) | NZ700470A (zh) |
SG (1) | SG11201405847SA (zh) |
UY (1) | UY34695A (zh) |
WO (1) | WO2013142371A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2899203B1 (en) * | 2008-05-08 | 2019-07-10 | Boehringer Ingelheim Animal Health USA Inc. | Leishmania vaccine using sand fly salivary immunogen |
US20130195918A1 (en) * | 2011-08-08 | 2013-08-01 | Dennis J. O'Callaghan | Equine Herpesvirus 1 Vaccine and Vector and Uses Thereof |
WO2015073507A1 (en) * | 2013-11-13 | 2015-05-21 | Cornell University | Stimulation of neonatal immunity |
WO2015123307A1 (en) | 2014-02-11 | 2015-08-20 | University Of Miami | Methods and compositions for transgene expression in a herpesvirus vector system |
AU2015343369B2 (en) | 2014-11-03 | 2018-11-22 | Georgia Tech Research Corporation | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
RU2736472C2 (ru) * | 2016-11-18 | 2020-11-17 | Общество с ограниченной ответственностью "ЭКСИФАРМ" | Химерный белок, синтетическая днк, кодирующая указанный белок, экспрессионный вектор, штамм-продуцент синтетической днк и способ получения плазмидной днк |
US11447562B2 (en) | 2017-01-01 | 2022-09-20 | Chi-Yu Gregory Lee | RP215 chimeric antigen receptor construct and methods of making and using same |
US11084272B2 (en) | 2017-05-31 | 2021-08-10 | General Electric Company | Test structure for additive manufacture and related method for emitter alignment |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4963481A (en) | 1985-12-18 | 1990-10-16 | Genetics Institute Inc | Promoter system |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
IE872455L (en) | 1986-09-12 | 1988-03-12 | Lanstrase Ltd | Improved recombinant expression |
IL84154A0 (en) | 1986-10-16 | 1988-03-31 | Microgenesys Inc | Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
DE3743138A1 (de) | 1987-12-18 | 1989-09-14 | Mayr Christian Gmbh & Co Kg | Schleifringlose, elektromagnetische ueberlastkupplung |
CA2003300A1 (en) | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Skin test and test kit for aids |
JP3602530B2 (ja) | 1991-03-07 | 2004-12-15 | ヴァイロジェネティクス コーポレイション | 遺伝子操作したワクチン菌株 |
US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
DE69417717T2 (de) * | 1993-12-20 | 1999-10-07 | Akzo Nobel Nv | Impstoff zum Schutze von Pferden gegen Pferdeherpesvirus-Infektionen |
JPH11504631A (ja) | 1995-04-25 | 1999-04-27 | バイカル インコーポレイテッド | Dna/脂質複合体の単一バイアル製剤 |
EP0803573A1 (en) | 1996-04-25 | 1997-10-29 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Polycistronic expression construct with cytokines for multivalent vaccines |
US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
JP2002512501A (ja) | 1996-07-03 | 2002-04-23 | メリアル インコーポレイテッド | 外来性dnaを含む組換えイヌアデノウィルス(cav) |
GB9625968D0 (en) * | 1996-12-13 | 1997-01-29 | Univ Glasgow | Vaccine |
FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
FR2776928B1 (fr) | 1998-04-03 | 2000-06-23 | Merial Sas | Vaccins adn adjuves |
TWI224107B (en) | 1998-10-22 | 2004-11-21 | Pfizer Prod Inc | Novel proteins from actinobacillus pleuropneumoniae |
US6017537A (en) | 1998-12-18 | 2000-01-25 | Connaught Laboratories, Inc. | Formyl methionyl peptide vaccine adjuvant |
US6645740B1 (en) | 1999-06-10 | 2003-11-11 | Merial Limited | Nucleic acids encodings equine GM-CSF |
FR2796397B1 (fr) | 1999-07-16 | 2006-09-01 | Merial Sas | Genes de calicivirus felin et vaccins notamment vaccins recombines |
RS50325B (sr) | 1999-09-25 | 2009-09-08 | University Of Iowa Research Foundation, | Imunostimulatorne nukleinske kiseline |
US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
MXPA03000823A (es) * | 2000-07-27 | 2003-09-10 | Res Corp Technologies Inc | Vacunas para el virus del herpes simple equino del tipo 1: mutaciones de los viruses que se refugian dentro del gen precoz inmediato. |
US20030059934A1 (en) * | 2001-04-03 | 2003-03-27 | Nikolaus Osterrieder | Artificial chromosomes comprising EHV sequences |
DE10116594A1 (de) * | 2001-04-03 | 2002-10-10 | Boehringer Ingelheim Vetmed | Künstliche Chromosomen, die EHV-Sequenzen umfassen |
FR2829498B1 (fr) | 2001-09-11 | 2003-11-28 | Merial Sas | Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins |
US7078507B2 (en) | 2001-11-09 | 2006-07-18 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Synthetic genes for malarial proteins and methods of use |
AU2003245416A1 (en) | 2002-06-07 | 2004-04-30 | University Of Florida | Endodontic files made using bulk metallic glasses |
AR040601A1 (es) | 2002-07-19 | 2005-04-13 | Boehringer Ingelheim Vetmed | Mutantes ehv negativos de gm sin elementos heterologos |
WO2004011677A2 (en) * | 2002-07-26 | 2004-02-05 | Animal Health Trust | Viral marker |
EP1394258A1 (en) * | 2002-08-30 | 2004-03-03 | Geneart GmbH | Non-human herpesviruses as vectors |
EP1765387B1 (en) | 2004-06-04 | 2013-01-09 | Merial Limited | NEEDLE-FREE ADMINISTRATION OF FeLV VACCINES |
US8986706B2 (en) | 2010-08-31 | 2015-03-24 | Merial, Inc. | Newcastle disease virus vectored herpesvirus vaccines |
-
2013
- 2013-03-15 US US13/840,935 patent/US8916371B2/en active Active
- 2013-03-15 BR BR112014023414-0A patent/BR112014023414B1/pt active IP Right Grant
- 2013-03-15 EP EP13719247.2A patent/EP2827897B1/en active Active
- 2013-03-15 MX MX2014011281A patent/MX355443B/es active IP Right Grant
- 2013-03-15 CN CN201380023248.3A patent/CN104302319B/zh active Active
- 2013-03-15 SG SG11201405847SA patent/SG11201405847SA/en unknown
- 2013-03-15 CA CA2867893A patent/CA2867893C/en active Active
- 2013-03-15 HU HUE13719247A patent/HUE042396T2/hu unknown
- 2013-03-15 ES ES13719247T patent/ES2711878T3/es active Active
- 2013-03-15 NZ NZ700470A patent/NZ700470A/en unknown
- 2013-03-15 JP JP2015501820A patent/JP6201166B2/ja active Active
- 2013-03-15 AU AU2013235423A patent/AU2013235423B2/en active Active
- 2013-03-15 WO PCT/US2013/032491 patent/WO2013142371A1/en active Application Filing
- 2013-03-20 AR ARP130100918A patent/AR090450A1/es active IP Right Grant
- 2013-03-20 UY UY0001034695A patent/UY34695A/es active IP Right Grant
-
2014
- 2014-11-17 US US14/543,300 patent/US9555101B2/en active Active
-
2015
- 2015-02-23 HK HK15101831.4A patent/HK1201205A1/zh unknown
-
2022
- 2022-02-21 AR ARP220100361A patent/AR124928A2/es unknown
Non-Patent Citations (3)
Title |
---|
"Analysis of equid herpesvirus 1 strain variation reveals a point mutation of the DNA polymerase strongly associated with neuropathogenic versus nonneuropathogenic disease outbreaks";J.Nugent et al.;《Journal of Virology》;20060401;第80卷(第8期);Table7 * |
"Construction and characterization of an equine herpesvirus 1 glycoprotein C negative mutant";Nikolaus Osterrieder et al.;《Virus Research》;19990201;第59卷(第2期);摘要,Fig 1和3.7 * |
"Isolation of equine herpesvirus-1 lacking glycoprotein C from from a dead neonatal foal in Japan";R.Kirisawa et al.;《Arch Virol》;20051201;第150卷(第12期);第2553页Nucleotide sequence accession number * |
Also Published As
Publication number | Publication date |
---|---|
CN104302319A (zh) | 2015-01-21 |
HUE042396T2 (hu) | 2019-06-28 |
AU2013235423B2 (en) | 2017-03-30 |
US20130251747A1 (en) | 2013-09-26 |
US20150190502A1 (en) | 2015-07-09 |
JP2015512395A (ja) | 2015-04-27 |
MX355443B (es) | 2018-04-18 |
US8916371B2 (en) | 2014-12-23 |
AR124928A2 (es) | 2023-05-17 |
BR112014023414A8 (pt) | 2022-07-05 |
BR112014023414A2 (pt) | 2017-07-11 |
CA2867893C (en) | 2022-09-20 |
CA2867893A1 (en) | 2013-09-26 |
HK1201205A1 (zh) | 2015-08-28 |
EP2827897B1 (en) | 2018-10-31 |
AR090450A1 (es) | 2014-11-12 |
BR112014023414B1 (pt) | 2022-08-30 |
NZ700470A (en) | 2016-04-29 |
AU2013235423A1 (en) | 2014-10-16 |
ES2711878T3 (es) | 2019-05-08 |
US9555101B2 (en) | 2017-01-31 |
UY34695A (es) | 2013-10-31 |
JP6201166B2 (ja) | 2017-09-27 |
EP2827897A1 (en) | 2015-01-28 |
SG11201405847SA (en) | 2014-10-30 |
MX2014011281A (es) | 2015-05-11 |
WO2013142371A1 (en) | 2013-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104302319B (zh) | 包含突变的糖蛋白c的重组马疱疹病毒-1疫苗及其用途 | |
JP6368725B2 (ja) | 豚ヘルペスウイルス遺伝子欠失株、ワクチン組成物及びその製造方法と応用 | |
EP3230305B1 (en) | Cytomegalovirus antigens | |
CN110551695A (zh) | 非洲猪瘟病毒四基因缺失弱毒株及其应用 | |
WO2017106736A1 (en) | Pseudorabies virus (prv) vector expressing heterologous polypeptides | |
CN111825768B (zh) | 基于自组装铁蛋白纳米抗原颗粒及流感疫苗和制备方法 | |
KR20150036057A (ko) | 재조합체 btv 및 ahsv 백신 | |
CN105018433A (zh) | 猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用 | |
EP0538299A1 (en) | Equine herpesvirus-4 tk?- vaccine | |
CN103957932B (zh) | 包含最优化的猫白血病病毒包膜基因的重组猫白血病病毒疫苗 | |
WO1994003628A1 (en) | Recombinant equine herpesviruses | |
CN105018436B (zh) | 猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用 | |
CA3202140A1 (en) | Genomic deletion in african swine fever vaccine allowing efficient growth in stable cell lines | |
EP0668355A1 (en) | Vaccine for the protection of horses against equine herpesvirus infection | |
SG183282A1 (en) | Method for producing recombinant virus | |
US10434165B2 (en) | FCV recombinant vaccines and uses thereof | |
CN103739697A (zh) | 抵抗猪伪狂犬病毒增殖的重组蛋白及其应用 | |
MXPA02002904A (es) | Vacuna de virus de laringotraqueitis infecciosa recombinante. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: MERIAL Free format text: FORMER OWNER: MERIAL LIMITED Effective date: 20150413 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150413 Address after: Georgia, USA Applicant after: Merial Address before: Georgia, USA Applicant before: Merial Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190712 Address after: Georgia Patentee after: Bollinger Ingham Animal Health USA Address before: Georgia Patentee before: Merial |